Intestinal Bacteria/ Probiotics

The Gluten File

On PubMed:

Therefore, B. longum CECT 7347 might ameliorate gliadin toxicity and modify the responses of intestinal epithelial cells to the gliadin challenge.
Influence of Bifidobacterium longum CECT 7347 and gliadin peptides on intestinal epithelial cell proteome.
PMID:21651295 July 2011

Bifidobacteria inhibit the inflammatory response induced by gliadins in intestinal epithelial cells via modifications of toxic peptide generation during digestion.
PMID: 20052669  Jan 2010

The impact of probiotic on gut health.
PMID: 19149514  Jan 2009

Immunomodulatory effect of probiotic bacteria.
PMID: 19149747  2009

These findings suggest that the gliadin-specific enteropathy is not merely related to the HLA DQ8-restricted massive production of IFNgamma, but additional parameters are involved. Moreover, our data imply that the intrinsic adjuvanticity of L. casei can be exploited to further enhance both mucosal and systemic T cell-mediated responses.
Adjuvant effect of Lactobacillus casei in a mouse model of gluten sensitivity.
PMID: 18547649  Aug 2008

CONCLUSIONS: Reductions in total Bifidobacterium and B. longum populations were associated with both active and non-active CD when compared to controls. These bacterial groups could constitute novel targets for adjuvant dietary therapies although the confirmation of this hypothesis would require further investigations.
Imbalances in faecal and duodenal Bifidobacterium species composition in active and non-active coeliac disease.
PMID: 19102766  Dec 2008

RESULTS: Bacteroides and C. leptum groups were more abundant in faeces and biopsies of CD patients than in controls regardless the stage of the disease. E. coli and Staphylococcus counts were also higher in faeces and biopsies of non-treated CD patients than in those of controls but their levels were normalized after treatment with a GFD. Bifidobacterium levels were lower in faeces of both CD patients as well as in biopsies of untreated CD patients compared to controls. Similar bacterial groups were related to CD in biopsies and faeces, indicating that faecal microbiota partly reflects that of the small intestine in CD patients, and could constitute a convenient biological index of this disorder. CONCLUSIONS: Duodenal and faecal microbiota is unbalanced in children with untreated CD and only partially restored after long-term treatment with a GFD, constituting a novel factor linked to this disorder.
Specific duodenal and faecal bacterial groups are associated with paediatric celiac disease.
PMID: 18996905  Nov 2008

CONCLUSIONS: The intestinal microbiota of CD patients could contribute to the Th1 pro-inflammatory milieu characteristic of the disease, while B. longum ES1 and B. bifidum ES2 could reverse these deleterious effects. These findings hold future perspectives of interest in CD therapy.
Bifidobacterium strains suppress in vitro the pro-inflammatory milieu triggered by the large intestinal microbiota of coeliac patients.
PMID: 18980693 Nov 2008

In conclusion, probiotics are effective in the treatment and/or prevention of a number of conditions, including diarrhoea, irritable bowel syndrome and atopic dermatitis, and the product used should be selected based on the particular indication.
Probiotics in allergy management.
PMID: 18931598  Nov 2008

Conclusion: Peptide bioactive factors from Bifidobacteria infantis retain their biological activity in vivo and are effective in normalizing gut permeability and improving disease in an animal model of colitis. The effects of BiCM are mediated in part by changes in MAP kinases and tight junction proteins.
Secreted bioactive factors from Bifidobacterium infantis enhance epithelial cell barrier function.
PMID: 18787064 Sept 2008

B. lactis inhibited the gliadin-induced increase dose-dependently in epithelial permeability, higher concentrations completely abolishing the gliadin-induced decrease in transepithelial resistance. The same bacterial strain also inhibited the formation of membrane ruffles in Caco-2 cells induced by gliadin administration. Furthermore, it also protected the tight junctions of Caco-2 cells against the effects of gliadin, as evinced by the pattern of ZO-1 expression. We conclude thus that live B. lactis bacteria can counteract directly the harmful effects exerted by coeliac-toxic gliadin and would clearly warrant further studies of its potential as a novel dietary supplement in the treatment of coeliac disease.
Live probiotic Bifidobacterium lactis bacteria inhibit the toxic effects induced by wheat gliadin in epithelial cell culture.
PMID: 18422736   June 2008

Probiotics: Use in Allergic Disorders: A Nutrition, Allergy, Mucosal Immunology, and Intestinal Microbiota (NAMI) Research Group
PMID: 18542035 June 2008

Probiotics, Prebiotics, and Synbiotics.
PMID: 18461293 May 2008

Probiotics and autoimmunity: An evolutionary perspective.
PMID: 17720327 Aug 2007

The use of probiotics, once discussed primarily in the context of alternative medicine, is now entering mainstream medicine. However, only a few of the potential health benefits attributed to probiotics have been confirmed in well-designed, well-conducted, randomized, controlled trials. This is especially true in the pediatric population. We review here the available evidence on efficacy of probiotics in children in the prevention and treatment of gastrointestinal diseases. Although we restrict our analysis to the pediatric age, whenever potentially relevant information is available only from adult studies, they are examined as well. Probiotics have been most extensively studied in the treatment of diarrheal diseases, where their efficacy can be considered well established. Studies documenting effects in other childhood gastrointestinal illnesses are few, although some preliminary results are promising. Furthermore, only a limited number of probiotic strains have been tested, and, as the effects of different probiotic microorganisms are not equivalent, results cannot be generalized. Thus, at present, we have some positive certainties, lots of exciting promises and many unanswered questions. Probiotics in gastrointestinal diseases in children: hard and not-so-hard evidence of efficacy.
PMID: 16707966 May 2006